as of 08-28-2026 3:59pm EST
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 114.6M | IPO Year: | 2017 |
| Target Price: | N/A | AVG Volume (30 days): | 25.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.68 | EPS Growth: | 33.33 |
| 52 Week Low/High: | $31.55 - $44.28 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -4.95 | Index: | N/A |
| Free Cash Flow: | -33124000.0 | FCF Growth: | N/A |
SEC 8-K filings with transcript text
Aug 13, 2026
See how YARW stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "YARW Yarrow Bioscience Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.